Pancreatic Cancer Research

ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Yee Chao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5578-340X; OpenAlex author ID A5026090288, A5038451182. Sources: ClinicalTrials.gov.

Their work

Papers
8
Trials
1
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Comprehensive review of current management and precision medicine in pancreatic cancer. Co-author DOI 10.1097/jcma.0000000000001365↗
  2. Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis. Co-author DOI 10.1186/s12885-025-13896-5↗
  3. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal a… Co-author DOI 10.1016/j.ejca.2022.01.030↗
  4. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. Co-author DOI 10.1097/jcma.0000000000000650↗
  5. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.17220↗
  6. The clinical significance of esophagogastric varices in patients with advanced pancreatic cancer. Co-author DOI 10.1097/jcma.0000000000000609↗
  7. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Co-author DOI 10.18632/oncotarget.4216↗
  8. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2239-1↗

Trials 1

  1. The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib Study director NCT01608841↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chung‐Pin Li · 7 shared papers, 1 shared trial, 2005–2026 · strength 1.31
  2. Hung-Yuan Yu · 3 shared papers, 2022–2026 · strength 0.94
  3. Keng-Li Lan · 1 shared paper, 2022 · strength 0.16
  4. Fei‐Ting Hsu · 1 shared paper, 2022 · strength 0.16
  5. Yu-Jen Chen · 1 shared paper, 2021 · strength 0.14
  6. Ming‐Chih Hou · 1 shared paper, 2021 · strength 0.14
  7. Fa‐Yauh Lee · 1 shared paper, 2021 · strength 0.14
  8. Shin‐E Wang · 1 shared paper, 2022 · strength 0.11
  9. Shih‐Ming Hsu · 1 shared paper, 2022 · strength 0.11
  10. Long‐Sheng Lu · 1 shared paper, 2022 · strength 0.11
  11. Yuan‐Hung Wu · 1 shared paper, 2022 · strength 0.11
  12. Jack P. Wang · 2 shared papers, 2013–2015 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.